Monotherapy trials in unselected patients indicate an EGFR-driven minority ESCC subgroup who gain survival, symptomatic control, and health-related quality of life benefits from EGFR inhibitors [8, 9]. Here, EGFR is linked to esophageal squamous cell carcinoma.